Skip to main content <#maincontent>
 *Welcome *The University of Pittsburgh and the UPMC University of
Pittsburgh	home </home/>feedback
</feedback.asp?referedPage=/info/authors/instructions/Default.asp/>support
</support/>log on </registration/technical.asp?process=default>
 15-Jan-2008 

</home/>	</home/>	
<http://www.biomedcentral.com/info/mediainformation/>

 home </home/> | issues </currentissue/browse.asp> | articles
</articles/browse.asp?sort=Reviews> | reports
</reports/browse.asp?sort=book> | supplements </supplements/browse.asp>
| weblinks </weblinks/> | conferences </conferences/> | search </search>
| information </info/default.asp> | subscribe
<https://orders.biomedcentral.com/subscribe/breastcancerres/> | my
details </registration/>

	
information

  	
about </info/about/>
	 | 	
FAQs </info/faq/>
	 | 	
hints
and tips </info/hints/>
	 | 	
editorial board </edboard/>
	 | 	
topic areas </info/topics/default.asp>
	 | 	
instructions
for authors </info/instructions/default.asp>
	 | 	
media </info/media/>
	 | 	
press </info/press/press.asp>
	 | 	
contacts </info/contact/>


Printer-friendly version <?print=yes>
	


  Instructions for /Breast Cancer Research/ authors

General information <#h1general>
Manuscript text <#h1text>
Illustrations and figures <#h1figures>
Tables <#h1tables>
Additional files <#h1data>
Proofs and reprints <#h1proofs>
Style and language <#h1style>
	


  General information

/Breast Cancer Research/ is a multidisciplinary journal that publishes
research articles of exceptional interest in all areas of biology and
medicine relevant to breast cancer. Articles explore the biological
basis of breast cancer and the clinical application of this knowledge.
Clinical studies will usually be phase I and II clinical trials. The
journal also regularly publishes reviews, commentaries and reports on
topics related to this research. These are usually commissioned, but
suggestions in the form of a brief summary are welcome and should be
sent to the Editorial Office. <mailto:editorial@breast-cancer-research.com>

Online submission process

To facilitate rapid publication and to minimize administrative costs,
/Breast Cancer Research/ prefers online submission
</manuscript/default.asp?txt_jou_id=3003>. The submission process is
compatible with version 3.0 or later of Internet Explorer and Netscape
Navigator, and with most other modern web browsers. It can be used from
PC, Mac, or Unix platforms.

Files can be submitted as a batch, or one by one. The submission process
can be interrupted at any time - when users return to the site, they can
carry on where they left off.

See below for examples of acceptable word processor and graphics file
formats. Additional files of any type, such as movies, animations, or
original data files, can also be submitted as part of the publication.

During submission you will be asked to provide a cover letter. Please
use this to explain why your manuscript should be published in the
journal and to elaborate on any issues relating to our editorial
policies detailed in the instructions for authors.

You will also be asked to provide the names and contact details of 2-4
potential reviewers for your manuscript.

Assistance with the process of manuscript preparation and submission is
available from the editorial office (
editorial@breast-cancer-research.com
<mailto:editorial@breast-cancer-research.com>)

Article-processing charges
/Breast Cancer Research/ levies an article-processing charge for every
accepted article, to cover the costs incurred by open access
publication. In 2008 the article-processing charge is 950 (?1265,
US$1860). Generally, if the submitting author's institution is a BioMed
Central member <http://www.biomedcentral.com/info/about/instmembership>
the cost of the article processing charge is covered by the membership,
and no further charge is payable. In the case of authors whose
institutions are supporter members
<http://www.biomedcentral.com/info/about/supportersmembership> of BioMed
Central, however, a discounted article processing charge is payable by
the author. Please click here <http://www.biomedcentral.com/inst/> to
check if your institution is a BioMed Central member. We offer a 30
discount for manuscripts formatted with EndNote 5
<http://www.biomedcentral.com/info/ifora/endnote> (or later versions) or
Reference Manager 10 <http://www.biomedcentral.com/info/ifora/refman> or
created using Publicon
<http://www.biomedcentral.com/info/ifora/publicon>. We routinely waive
charges for authors from low-income countries. For further details, see
more information about article-processing charges </info/faq/apcfaq.asp>.

Policies

Any manuscript , or substantial parts of it, submitted to the journal
must not be under consideration by any other journal although it may
have been deposited on a preprint server. The manuscript should not have
already been published in any journal or other citable form, with the
exception that the journal is willing to consider peer-reviewing
manuscripts that are translations of articles originally published in
another language. In this case, the consent of the journal in which the
article was originally published must be obtained and the fact that the
article has already been published must be made clear on submission and
stated in the abstract. Authors are required to ensure that no material
submitted as part of a manuscript infringes existing copyrights, or the
rights of a third party. Authors who publish in /Breast Cancer Research/
retain copyright to their work ( more information
<http://www.biomedcentral.com/info/authors/license> ). The authors are
understood to give /Breast Cancer Research/ permission to reproduce the
article or portions of it for print and online distribution;
advertisements may be included to help defray the costs of handling and
distribution. Correspondence concerning articles published in /Breast
Cancer Research/ is encouraged. Correspondence containing data or
scientific argument is subject to peer-review.

Submission of a manuscript to /Breast Cancer Research/ implies that all
authors have read and agreed to its content, that readily replaceable
material described in the article will be freely distributed to academic
colleagues, and that any experimental research that is reported in the
manuscript has been performed with the approval of an appropriate ethics
committee. Research carried out on humans must be in compliance with the
Helsinki Declaration <http://www.wma.net/e/policy/b3.htm>, and any
experimental research on animals must follow internationally recognized
guidelines. A statement to this effect must appear in the Methods
section of the manuscript, including the name of the body which gave
approval, with a reference number where appropriate. Informed consent
must also be documented. Manuscripts may be rejected if the editorial
office considers that the research has not been carried out within an
ethical framework, e.g. if the severity of the experimental procedure is
not justified by the value of the knowledge gained.

Generic drug names should generally be used. When proprietary brands are
used in research, include the brand names in parentheses in the Methods
section.

We ask authors of /Breast Cancer Research/ papers to complete a
declaration of competing interests, <#interests> which should be
provided as a separate section of the manuscript, to follow the
Acknowledgements. Where an author gives no competing interests, the
listing will read 'The author(s) declare that they have no competing
interests'. Much has been written about competing interests (or conflict
of interest, as other journals call it) within scientific research, but
the following articles provide some background:

      R Smith: *Beyond conflict of interest.* /BMJ/ 1998, *317* :291-292
      <http://bmj.bmjjournals.com/cgi/content/full/317/7154/291>
      R Smith: *Making progress with competing interests.* /BMJ/ 2002,
      *325* :1375-1376
      <http://bmj.bmjjournals.com/cgi/content/full/325/7377/1375>
      CD DeAngelis, PB Fontanarosa, A Flanagin: *Reporting financial
      conflicts of interest and relationships between investigators and
      research sponsors.* /JAMA/ 2001, *286* :89-9
      <http://jama.ama-assn.org/cgi/content/full/286/1/89>
      K Morin, H Rakatansky, FA Riddick Jr, LJ Morse, JM O'Bannon 3rd,
      MS Goldrich, P Ray, M Weiss, RM Sade, MA Spillman: *Managing
      conflicts of interest in the conduct of clinical trials.* /JAMA/
      2002, *287* :78-84
      <http://jama.ama-assn.org/cgi/content/full/287/1/78> 

For all articles that include information or clinical photographs
relating to individual patients, written and signed consent from each
patient to publish must also be mailed or faxed to the editorial staff.
The manuscript should also include a statement to this effect in the
Acknowledgements section, as follows: "Written consent for publication
was obtained from the patient or their relative."

/Breast Cancer Research/ supports initiatives to improve the performance
and reporting of clinical trials, part of which includes prospective
registering and numbering of trials. While there are initiatives to
ensure that all clinical trials are registered (most notably the recent
statement from the International Committee of Medical Journal Editors -
see http://www.icmje.org/clin_trialup.htm), we are focussing on
controlled trials of healthcare interventions, for now. Authors of
protocols or reports of controlled trials of health care interventions
must register their trial prior to submission in a suitable publicly
accessible registry. The trial registers that currently meet all of the
ICMJE guidelines can be found at http://www.icmje.org/faq.pdf.

The trial registration number should be included as the last line of the
abstract of the manuscript <#abstract>.

/Breast Cancer Research/ also supports initiatives aimed at improving
the reporting of biomedical research. Checklists have been developed for
randomized controlled trials (CONSORT
<http://www.consort-statement.org/index.aspx?o=1065>), systematic
reviews (QUOROM <http://www.consort-statement.org/index.aspx?o=1065>),
meta-analyses of observational studies (MOOSE
<http://www.consort-statement.org/index.aspx?o=1065>), diagnostic
accuracy studies (STARD
<http://www.consort-statement.org/index.aspx?o=1065>) and qualitative
studies (RATS <http://www.biomedcentral.com/info/ifora/rats>). Authors
are requested to make use of these when drafting their manuscript and
peer reviewers will also be asked to refer to these checklists when
evaluating these studies. For authors of systematic reviews, a
supplementary file, linked from the Methods section, should reproduce
all details concerning the search strategy. For an example of how a
search strategy should be presented, see the Cochrane Reviewers'
Handbook
<http://www.cochrane.dk/cochrane/handbook/5_locating_and_selecting_studies/5_2_developing_and_documenting_a_search_strategy_for_studies_and_organizing_search_results.htm>.


Authors from pharmaceutical companies, or other commercial organizations
that sponsor clinical trials, should adhere to the Good Publication
Practice guidelines for pharmaceutical companies
<http://www.gpp-guidelines.org/>, which are designed to ensure that
publications are produced in a responsible and ethical manner. The
guidelines also apply to any companies or individuals that work on
industry-sponsored publications, such as freelance writers, contract
research organizations and communications companies.

The involvement of medical writers or anyone else who assisted with the
preparation of the manuscript content should be acknowledged, along with
their source of funding, as described in the European Medical Writers
Association (EMWA) guidelines on the role of medical writers in
developing peer-reviewed publications
<http://www.emwa.org/Mum/EMWAguidelines.pdf>. If medical writers are not
listed among the authors, it is important that their role be
acknowledged explicitly. We suggest wording such as 'We thank Jane Doe
who provided medical writing services on behalf of XYZ Pharmaceuticals
Ltd.'.

Nucleic acid sequences, protein sequences and atomic coordinates should
be deposited in an appropriate database in time for the accession number
to be included in the article. Where appropriate, authors should adhere
to the standards proposed by the Microarray Gene Expression Data Society
(http://www.mged.org) and must deposit microarray data in one of the
public repositories, such as ArrayExpress
(http://www.ebi.ac.uk/arrayexpress), Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/projects/geo/) or the Center for Information
Biology Gene Expression Database (CIBEX; http://cibex.nig.ac.jp).

Any 'in press' articles cited within the references and necessary for
the reviewers' assessment of the manuscript should be made available if
requested by the editorial office.

BioMed Central is a member of the Committee on Publication Ethics
(COPE). Authors who have appealed against a rejection but remain
concerned about the editorial process can refer their case to COPE. For
more information, visit www.publicationethics.org.uk
<http://www.publicationethics.org.uk>.

BioMed Central endorses the World Association of Medical Editors (WAME)
Policy Statement on Geopolitical Intrusion on Editorial Decisions
<http://www.wame.org/wamestmt.htm#geopolitical>.

Immediate publication on acceptance

Once an original research article is accepted, it is published in
/Breast Cancer Research/ immediately as a provisional PDF file, with a
final citation, and will be included in PubMed. The article will
subsequently be copyedited and published in both a fully browseable web
form and as a formatted PDF; the article will then be available through
/Breast Cancer Research/, BioMed Central and PubMed Central.

	return to top <#top>
General information <#h1general>
Manuscript text <#h1text>
Illustrations and figures <#h1figures>
Tables <#h1tables>
Additional files <#h1data>
Proofs and reprints <#h1proofs>
Style and language <#h1style>
	


  Preparing main manuscript text

File formats
The following word processor file formats are acceptable for the main
manuscript document:

    * Microsoft Word (version 2 and above)
    * Rich text format (RTF)
    * TeX/LaTeX (use BioMed Central's TeX template)
      <http://www.biomedcentral.com/info/ifora/tex>

Users of other word processing packages should save or convert their
files to RTF before uploading. Many free tools are available which ease
this process.

TeX/LaTeX users: We recommend using BioMed Central's TeX template and
BibTeX stylefile <http://www.biomedcentral.com/info/ifora/tex>. If you
use this standard format, you can submit your manuscript in TeX format
(after you submit your TEX file, you will be prompted to submit your BBL
file). If you have used another template for your manuscript, or if you
do not wish to use BibTeX, then please submit your manuscript as an RTF
file.

Publicon users: Information about Publicon
<http://www.biomedcentral.com/info/ifora/publicon> and instructions for
authoring in Publicon
<http://www.biomedcentral.com/info/ifora/publiconinstructions> are
available.

Note that figures <#h1figures> must be submitted as separate image
files, not as part of the submitted DOC/ TEX file.

Manuscript sections for Research articles
Manuscripts for Research articles submitted to /Breast Cancer Research/
should be divided into the following sections:

    * Title page <#title>
    * Abstract <#abstract>
    * Introduction <#introduction>
    * Materials and Methods <#mandm>
    * Results <#results>
    * Discussion <#discussion>
    * Conclusions <#conclusions>
    * List of abbreviations used <#abbreviations> (if any)
    * Competing interests <#interests>
    * Authors' contributions <#authorscon>
    * Acknowledgements <#acknowledgements>
    * References <#references>
    * Figure legends <#legends> (if any)
    * Tables and captions <#h1tables> (if any)
    * Description of additional data files <#h1data> (if any)

The *Accession Numbers* of any nucleic acid sequences, protein sequences
or atomic coordinates cited in the manuscript should be provided, in
square brackets and include the corresponding database name; for
example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845,
PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].

The databases for which we can provide direct links are: EMBL Nucleotide
Sequence Database (EMBL <http://www.ebi.ac.uk/embl/>), DNA Data Bank of
Japan (DDBJ <http://www.ddbj.nig.ac.jp> ), GenBank at the NCBI (GenBank
<http://www.ncbi.nlm.nih.gov/Genbank/index.html>), Protein Data Bank
(PDB <http://www.rcsb.org/pdb/>), Protein Information Resource (PIR
<http://pir.georgetown.edu/>) and the Swiss-Prot Protein Database
(Swiss-Prot <http://us.expasy.org/sprot/>).

*Title page*
This should list the title of the article. The title should include the
study design, for example:

*A versus B in the treatment of C: a randomized controlled trial*

*X is a risk factor for Y: a case control study*

The full names, institutional addresses, and e-mail addresses for all
authors must be included on the title page. The corresponding author
should also be indicated.

*Abstract*
The abstract of the manuscript should not exceed 350 words and must be
structured into separate sections: *Background*, the context and purpose
of the study; *Methods*, how the study was performed and statistical
tests used; *Results*, the main findings; *Conclusions*, brief summary
and potential implications. Please minimize the use of abbreviations and
do not cite references in the abstract. *Trial Registration*, if your
research article reports the results of a controlled health care
intervention, please list your trial registry, along with the unique
identifying number, e.g. *Trial registration*: Current Controlled Trials
ISRCTN73824458. Please note that there should be no space between the
letters and numbers of your trial registration number.

*Introduction*
This should be written from the standpoint of researchers without
specialist knowledge in that area and must clearly state - and, if
helpful, illustrate - the background to the research and its aims.
Reports of clinical research should, where appropriate, include a
summary of a search of the literature to indicate why this study was
necessary and what it aimed to contribute to the field. The section
should end with a very brief statement of what is being reported in the
article.

*Materials and methods*
This should include the design of the study, the setting, the type of
participants or materials involved, a clear description of all
interventions and comparisons, and the type of analysis used, including
a power calculation if appropriate.

*Results and Discussion*
The Results and Discussion may be combined into a single section or
presented separately. Results of statistical analysis should include,
where appropriate, relative and absolute risks or risk reductions, and
confidence intervals. The Results and Discussion sections may also be
broken into subsections with short, informative headings.

*Conclusions*
This should state clearly the main conclusions of the research and give
a clear explanation of their importance and relevance. Summary
illustrations may be included.

*List of abbreviations*
If abbreviations are used in the text they should be defined in the text
where first used and a list of abbreviations should be provided, which
should precede the competing interests and authors' contributions.

*Competing interests*
A competing interest exists when your interpretation of data or
presentation of information may be influenced by your personal or
financial relationship with other people or organizations. Authors
should disclose any financial competing interests but also any
non-financial competing interests that may cause them embarrassment were
they to become public after the publication of the manuscript.

Authors are required to complete a declaration of competing interests.
All competing interests that are declared will be listed at the end of
published articles. Where an author gives no competing interests, the
listing will read 'The author(s) declare that they have no competing
interests'.

When completing your declaration, please consider the following questions:

/Financial competing interests/

    * In the past five years have you received reimbursements, fees,
      funding, or salary from an organization that may in any way gain
      or lose financially from the publication of this manuscript,
      either now or in the future? Is such an organization financing
      this manuscript (including the article-processing charge)? If so,
      please specify.
    * Do you hold any stocks or shares in an organization that may in
      any way gain or lose financially from the publication of this
      manuscript, either now or in the future? If so, please specify.
    * Do you hold or are you currently applying for any patents relating
      to the content of the manuscript? Have you received
      reimbursements, fees, funding, or salary from an organization that
      holds or has applied for patents relating to the content of the
      manuscript? If so, please specify.
    * Do you have any other financial competing interests? If so, please
      specify.

/Non-financial competing interests/

Are there any non-financial competing interests (political, personal,
religious, ideological, academic, intellectual, commercial or any other)
to declare in relation to this manuscript? If so, please specify.

If you are unsure as to whether you, or one your co-authors, has a
competing interest please discuss it with the editorial office.

*Authors' contributions*
In order to give appropriate credit to each author of a paper, the
individual contributions of authors to the manuscript should be
specified in this section.

An "author" is generally considered to be someone who has made
substantive intellectual contributions to a published study. To qualify
as an author one should 1) have made substantial contributions to
conception and design, or acquisition of data, or analysis and
interpretation of data; 2) have been involved in drafting the manuscript
or revising it critically for important intellectual content; and 3)
have given final approval of the version to be published. Each author
should have participated sufficiently in the work to take public
responsibility for appropriate portions of the content. Acquisition of
funding, collection of data, or general supervision of the research
group, alone, does not justify authorship.

We suggest the following kind of format (please use initials to refer to
each author's contribution): AB carried out the molecular genetic
studies, participated in the sequence alignment and drafted the
manuscript. JY carried out the immunoassays. MT participated in the
sequence alignment. ES participated in the design of the study and
performed the statistical analysis. FG conceived of the study, and
participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.

All contributors who do not meet the criteria for authorship should be
listed in an acknowledgements section. Examples of those who might be
acknowledged include a person who provided purely technical help,
writing assistance, or a department chair who provided only general support.

*Acknowledgements*
Please acknowledge anyone who contributed towards the study by making
substantial contributions to conception, design, acquisition of data, or
analysis and interpretation of data, or who was involved in drafting the
manuscript or revising it critically for important intellectual content,
but who does not meet the criteria for authorship. Please also include
their source(s) of funding. Please also acknowledge anyone who
contributed materials essential for the study.

The role of a medical writer must be included in the acknowledgements
section, including their source(s) of funding.

Authors should obtain permission to acknowledge from all those mentioned
in the Acknowledgements.

Please list the source(s) of funding for the study, for each author, and
for the manuscript preparation in the acknowledgements section. Authors
must describe the role of the funding body, if any, in study design; in
the collection, analysis, and interpretation of data; in the writing of
the manuscript; and in the decision to submit the manuscript for
publication.

*References*
All references must be numbered consecutively, in square brackets, in
the order in which they are cited in the text, followed by any in tables
or legends. Reference citations should not appear in titles or headings.
Each reference must have an individual reference number. Please avoid
excessive referencing. If automatic numbering systems are used, the
reference numbers must be finalized and the bibliography must be fully
formatted before submission.

Only articles and abstracts that have been published or are in press, or
are available through public e-print/preprint servers, may be cited;
unpublished abstracts, unpublished data and personal communications
should not be included in the reference list, but may be included in the
text. Notes/footnotes are not allowed. Obtaining permission to quote
personal communications and unpublished data from the cited author(s) is
the responsibility of the author. Journal abbreviations follow Index
Medicus/MEDLINE. For each reference, name all authors unless there are
more than ten, in which case name the first ten followed by /et al./

We encourage authors to use a recent version of EndNote (version 5 and
above) or Reference Manager (version 10) when formatting their reference
list, as this allows references to be automatically extracted. Authors
submitting articles in EndNote 5 or higher or Reference Manager 10
format will save 30 on the 950 (?1265, US$1860) article processing
charge. In order to obtain this discount, you should upload the
manuscript file containing your EndNote or Reference Manager-formatted
bibliography as a .doc file. Please ensure you do not convert to another
format (e.g. RTF or PDF). On upload, the discount will be automatically
granted and you will receive a confirmation on-screen and by email. You
will also be able to preview an HTML version of the extracted references
during submission, and we urge authors to check this. EndNote or
Reference Manager users should also make sure that any changes made to
the reference list are done within their reference management program,
rather than by manually editing the formatted bibliography. This is
because manually introduced changes will not be picked up in the
automatically extracted list.

Further details about EndNote
<http://www.biomedcentral.com/info/endnote.asp> and Reference Manager
<http://www.biomedcentral.com/info/ifora/refman> are available on the
BioMed Central site, including style files that conform to the BioMed
Central style and information about how to upgrade. Users of other
reference management programs should be able to select other journal
styles that output a numeric list styled similarly to the guide below.

For EndNote users, we provide a detailed technical guide
<http://www.biomedcentral.com/info/ifora/endnote/#technicalhelp> to help
with resolving problems that are encountered with the automated
reference extraction process. Please check that your reference
extraction is accurate after uploading the manuscript text file.

We are also working towards integrating data from RefWorks referencing
software. We are working in partnership with the development team of
RefWorks <http://www.refworks.com/> to produce a high quality extraction
process.

Examples of the /Breast Cancer Research/ reference style are shown
below. Please take care to follow the reference style precisely;
references not in the correct style may be retyped, necessitating
tedious proofreading.

Links
Web links and URLs should be included in the reference list. They should
be provided in full, including both the title of the site and the URL,
in the following format: *The Mouse Tumor Biology Database*
[http://tumor.informatics.jax.org/cancer_links.html]

/Breast Cancer Research/ reference style

/Article within a journal/
1. Koonin EV, Altschul SF, Bork P: *BRCA1 protein products: functional
motifs.* /Nat Genet/ 1996, *13:*266-267.

/Article within a journal supplement /
2. Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: *Analysis and
assessment of ab initio three-dimensional prediction, secondary
structure, and contacts prediction.* /Proteins/ 1999, *Suppl 3:*149-170.

/In press article/
3. Kharitonov SA, Barnes PJ: *Clinical aspects of exhaled nitric
oxide.* /Eur Respir J/, in press.

/Published abstract/
4. Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN:
*Mesenchymal cells, stromal derived factor-1 and rheumatoid arthritis
[abstract].* /Arthritis Rheum/ 1999, *42:*s250.

/Article within conference proceedings/
5. Jones X: *Zeolites and synthetic mechanisms.* In /Proceedings of the
First National Conference on Porous Sieves: 27-30 June 1996; Baltimore./
Edited by Smith Y. Stoneham: Butterworth-Heinemann; 1996:16-27.

/Book chapter, or article within a book/
6. Schnepf E: *From prey via endosymbiont to plastids: comparative
studies in dinoflagellates.* In /Origins of Plastids. Volume 2./ 2nd
edition. Edited by Lewin RA. New York: Chapman and Hall; 1993:53-76.

/Whole issue of journal/
7. Ponder B, Johnston S, Chodosh L (Eds): *Innovative oncology.* In
/Breast Cancer Res/ 1998, *10:*1-72.

/Whole conference proceedings/
8. Smith Y (Ed): /Proceedings of the First National Conference on Porous
Sieves: 27-30 June 1996; Baltimore./ Stoneham: Butterworth-Heinemann; 1996.

/Complete book/
9. Margulis L: /Origin of Eukaryotic Cells./ New Haven: Yale University
Press; 1970.

/Monograph or book in a series/
10. Hunninghake GW, Gadek JE: *The alveolar macrophage.* In /Cultured
Human Cells and Tissues./ Edited by Harris TJR. New York: Academic
Press; 1995:54-56. [Stoner G (Series Editor): /Methods and Perspectives
in Cell Biology,/ vol 1.]

/Book with institutional author/
11. Advisory Committee on Genetic Modification: /Annual Report./ London;
1999.

/PhD thesis/
12. Kohavi R: *Wrappers for performance enhancement and oblivious
decision graphs.* /PhD thesis./ Stanford University, Computer Science
Department; 1995.

/Link / URL/
13. *The Mouse Tumor Biology Database*
[http://tumor.informatics.jax.org/cancer_links.html]

	return to top <#top>

General information <#h1general>
Manuscript text <#h1text>
Illustrations and figures <#h1figures>
Tables <#h1tables>
Additional files <#h1data>
Proofs and reprints <#h1proofs>
Style and language <#h1style>
	


  Preparing illustrations and figures

Figures should be provided as separate files . Each figure should
comprise only a single file. There is no charge for the use of color.

Please read our figure preparation guidelines
<http://www.biomedcentral.com/info/ifora/figures> for detailed
instructions on maximising the quality of your figures
<http://www.biomedcentral.com/info/ifora/figuretypes> , for further
information please contact the Editorial Office < mailto:
editorial@breast-cancer-research.com> .

Formats
The following file formats can be accepted. Detailed information for
each file type can be found by clicking on individual links.

    * EPS (suitable for diagrams and/or images)
    * PDF (suitable for diagrams and/or images)
    * Microsoft Word (suitable for diagrams and/or images, figures must
      be a single page)
    * PowerPoint (suitable for diagrams and/or images, figures must be a
      single page)
    * TIFF (suitable for images)
    * JPEG (suitable for photographic images, less suitable for
      graphical images)
    * PNG (suitable for images)
    * BMP (suitable for images)

/Breast Cancer Research/ will edit all figures supplied by the author.
For this reason it is especially important that authors should supply
figures in vector form
<http://www.biomedcentral.com/info/ifora/figures#bitmapvector>, to
facilitate such editing.

Figure legends
All figure legends should start with a single sentence that acts as the
figure's title. The legends should be included in the main manuscript
text file immediately following the references, rather than being a part
of the figure file. For each figure, the following information should be
provided: Figure number (in sequence, using Arabic numerals - i.e.
Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed
legend, up to 300 words.

*Please note that it is the responsibility of the author(s) to obtain
permission from the copyright holder* to reproduce figures or tables
that have previously been published elsewhere.

	return to top <#top>
General information <#h1general>
Manuscript text <#h1text>
Illustrations and figures <#h1figures>
Tables <#h1tables>
Additional files <#h1data>
Proofs and reprints <#h1proofs>
Style and language <#h1style>
	


  Preparing tables

Each table should be numbered in sequence using Arabic numerals (i.e.
Table 1, 2, 3 etc.). Tables should also have a title that summarizes the
whole table, maximum 15 words. Detailed legends may then follow, but
should be concise.

Tables integral to the manuscript can be pasted into the end of the
document text file, in portrait format (note that tables on a landscape
page must be reformatted onto a portrait page or submitted as additional
files). These will be typeset and displayed in the final published form
of the article. Such tables should be formatted using the 'Table object'
in a word processing program to ensure that columns of data are kept
aligned when the file is sent electronically for review; this will not
always be the case if columns are generated by simply using tabs to
separate text. Commas should not be used to indicate numerical values.
Color and shading should not be used.

Larger datasets can be uploaded separately as additional files.
Additional files will not be displayed in the final, published form of
the article, but a link will be provided to the files as supplied by the
author.

Tabular data provided as additional files can be uploaded as an Excel
spreadsheet (.xls) or comma separated values (.csv). As with all files,
please use the standard file extensions.

	return to top <#top>
General information <#h1general>
Manuscript text <#h1text>
Illustrations and figures <#h1figures>
Tables <#h1tables>
Additional files <#h1data>
Proofs and reprints <#h1proofs>
Style and language <#h1style>
	


  Preparing additional files

Web-only material
If there is necessary material that cannot be provided in the PDF
version, such as large datasets or movies, we will make it available on
the /Breast Cancer Research/ website with the electronic edition of the
article.

*Additional files*
If additional files are provided (e.g. movie files, original datafiles),
each should be described in this section of the manuscript, providing
the following information:

    * file name
    * file format (including name and URL link of appropriate viewer if
      format is unusual)
    * title of this dataset
    * description of this dataset.

Additional data files may be referenced generically within the body of
the article. e.g. "See additional data file 1 for the original data used
to perform this analysis". Additional files are considered integral to
articles published by /Breast Cancer Research/. There is no distinction
between the main article and 'supplementary material'. Files will be
virus-scanned on submission.

File formats
Files should not be platform-specific, and should be viewable using free
or widely available tools. The following are examples of suitable formats:

    * additional documentation - PDF (Adobe Acrobat) or TXT (plain text)
    * animations - SWF (Shockwave Flash)
    * movies - MOV (Quicktime) and MPG (MPEG)
    * tabular data - XLS (Excel spreadsheet) and CSV (Comma Separated
      Values)

File extensions
It is recommended that files be given the appropriate standard three
letter file extension for their file type (e.g. spreadsheet.xls or
table.csv). This is especially important for Macintosh users, since the
Macintosh operating system does not enforce the use of standard extensions.

Mini-websites
Small self-contained websites can be submitted as additional files, in
such a way that they will be browsable from within the full text HTML
version of the article. In order to do this, please follow these
instructions:

   1. Create a folder containing a starting file called index.html (or
      index.htm) in the root
   2. Put all files necessary for viewing the mini-website within the
      folder, or sub-folders
   3. Ensure that all links are relative (ie "images/picture.jpg" rather
      than "/images/picture.jpg" or
      "http://yourdomain.net/images/picture.jpg" or "C:\Documents and
      Settings\username\My Documents\mini-website\images\picture.jpg")
      and no link is longer than 255 characters
   4. Access the index.html file and browse around the mini-website, to
      ensure that the most commonly used browsers (Internet Explorer and
      Firefox) are able to view all parts of the mini-website without
      problems, it is ideal to check this on a different machine
   5. Compress the folder into a ZIP, check the file size is under 20
      MB, ensure that index.html is in the root of the ZIP, and that the
      file has .zip extension, then submit as an additional file with
      your article

	return to top <#top>
General information <#h1general>
Manuscript text <#h1text>
Illustrations and figures <#h1figures>
Tables <#h1tables>
Additional files <#h1data>
Proofs and reprints <#h1proofs>
Style and language <#h1style>
	


  Proofs and reprints

Proofs will be sent by email. Corrections should be returned within 2
days, preferably by fax or courier if sending paper proofs. Please
provide a typed list of corrections clearly indicating where the
corrections should be made and please send this list by e-mail. Any
substantial additions must be in the form of a note added in proof.

Reprints may be purchased for articles published. Prices are available
from the Editorial Office <mailto:editorial@breast-cancer-research.com>.

	return to top <#top>
General information <#h1general>
Manuscript text <#h1text>
Illustrations and figures <#h1figures>
Tables <#h1tables>
Additional files <#h1data>
Proofs and reprints <#h1proofs>
Style and language <#h1style>
	


  Style and language

General
Currently, /Breast Cancer Research/ can only accept manuscripts written
in English. Spelling should be US English or British English, but not a
mixture .

Gene names should be in italic, but protein products should be in plain
type.

There is no explicit limit on the length of articles submitted, but
authors are encouraged to be concise. There is no restriction on the
number of figures, tables or additional files that can be included with
each article online. Authors should include all relevant supporting data
with each article.

Help and advice on scientific writing
Tim Albert has produced for BioMed Central a list of tips
<http://www.biomedcentral.com/info/ifora/report> for writing a
scientific manuscript. MedBioWorld
<http://www.medbioworld.com/advice/presenting.html> also provides a list
of resources for science writing.

Abbreviations
Abbreviations should be used as sparingly as possible. They should be
defined when first used and a list of abbreviations should be provided
preceding the acknowledgements and references.

Typography

    * Please use double line spacing.
    * Type the text unjustified, without hyphenating words at line breaks.
    * Use hard returns only to end headings and paragraphs, not to
      rearrange lines.
    * Capitalize only the first word, and proper nouns, in the title.
    * All pages should be numbered.
    * Use the /Breast Cancer Research/ reference format.
    * Footnotes to text should not be used.
    * Greek and other special characters may be included. If you are
      unable to reproduce a particular special character, please type
      out the name of the symbol in full.
      *Please ensure that all special characters used are embedded in
      the text, otherwise they will be lost during conversion to PDF.*

Units
SI Units should be used throughout (liter and molar are permitted,
however).

Last revised: 3 October 2005

</manuscript/default.asp?txt_jou_id=3003>
	return to top <#top>


------------------------------------------------------------------------
<http://oas.biomedcentral.com/5c/breast-cancer-research.com/2048987474/Bottom/biomed/house_author_quotes_BCR_2007/BCR_author_quote.gif/38323331636532613437313336623630>


	
Published by
	<http://www.biomedcentral.com>

 1999-2008 BioMed Central Ltd unless otherwise stated * <
info@breast-cancer-research.com >*
<mailto:info@breast-cancer-research.com>   Terms and conditions
</info/terms.asp>

